Antidepressant Controlled Trial for Negative Symptoms in Schizophrenia
Status:
Completed
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
The aim of this double-blind, placebo-controlled trial is to establish the clinical and cost
effectiveness of an SSRI antidepressant, citalopram, in the management of persistent negative
symptoms of schizophrenia over a year.
Phase:
Phase 4
Details
Lead Sponsor:
Imperial College London
Collaborators:
King's College London University College, London University of Bristol University of Manchester University of Oxford University of Southampton